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Exocrine pancreatic insufficiency following gastrectomy and 
quality of life in patients undergoing gastric resection for 
malignancy 
 
Background 
 Gastrectomy for adenocarcinoma stomach is a major procedure that causes significant 
morbidity to the patient and can influence the quality of life of patients. One major 
concerns following gastrectomy is the complaints of post-operative steatorrhea and 
weight loss which is attributed to lipid malabsorption. One of the postulated causes of 
lipid malabsorption following gastrectomy and Roux en Y reconstruction is exocrine 
pancreatic enzyme insufficiency. 
 Aim and objectives 
To find the incidence of exocrine pancreas insufficiency following gastrectomy, for 
gastric cancer and to assess the quality of life in patients undergoing gastric resection 
for malignancy.  
Materials and Method 
 This was a cross-sectional study among patients undergoing gastric resection for 
adenocarcinoma in the Upper GI surgical unit, Department of General Surgery in 
Christian Medical College, Vellore. Patients planned for gastrectomy fulfilling the 
study recruitment criteria and consented for the study were tested for stool elastase pre-
operatively and post-operatively. Continuous sampling of all eligible patients were done 
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till sample size was reached. All patients who underwent gastrectomy for 
adenocarcinoma stomach during the study period in 2017 were assessed for quality of 
life using a semi structured questionnaire from a validated questionnaire EORTC QLQ 
C30 and EORTC QLQ STO22 during their postoperative period. Retrospective QOL 
analysis was performed on the patients who had undergone gastrectomy for 
adenocarcinoma stomach between the years 2013 and 2016. Data was entered using 
Epidata 3.1 and analysed using SPSS 23.  
Results 
The incidence of exocrine pancreatic insufficiency calculated by stool elastase testing 
in subtotal and total gastrectomy was 40% and 16.7% respectively. The overall 
incidence of exocrine pancreatic insufficiency in gastrectomy was 34.6% None of the 
patients in the study had significant clinical symptoms suggestive of steatorrhea or fat 
malabsorption. The was no statistical difference between total and subtotal gastrectomy 
with the incidence of exocrine pancreatic insufficiency. More number of patients at 1-
year follow-up have higher pain and eating restriction score which decreases as the 
follow up time period increases. Quality of life score was not influenced by the type of 
gastrectomy, method of surgery, stage of disease at presentation or the resection intent. 
As the follow up time period from time of surgery increases by a month, the overall 
quality of life score decreases by 2 points.  
Conclusions 
The incidence of exocrine pancreatic insufficiency following gastric resection for 
malignancy is low in our population compared to the Western data. Routine 
18 
 
supplementation of pancreatic enzyme supplements to all patients undergoing 
gastrectomy may not be required. However, screening for pancreatic insufficiency by 
stool elastase testing, in the subgroup of patients who are malnourished or have 
symptoms of fat malabsorption may help detect this problem, which can be addressed 
effectively by exocrine pancreatic supplementation.  
 
Keywords: Gastrectomy, Exocrine pancreatic insufficiency, Quality of life, Stool 
elastase 
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Stomach cancer is one of the most common cancers in India and also a major cause of 
cancer related death in India. Gastrectomy is the surgical option for the management of 
gastric adenocarcinoma along with neoadjuvant and adjuvant therapy. Gastrectomy is a 
major surgery which involves significant changes to the anatomy of the digestive tract 
of the patient. The long-term problems of gastrectomy would include steatorrhea caused 
by lipid malabsorption. Many theories have been postulated for the cause of 
malabsorption of lipids. Pancreatic insufficiency is one of the reasons postulated for the 
development of lipid malabsorption following gastrectomy. Establishing the presence 
of exocrine pancreatic deficiency would necessitate the need for studying the role of 
routine supplementation of pancreatic enzyme capsules for patients post-operatively to 
prevent lipid malabsorption symptoms.  Quality of life of patients with stomach cancer 
following surgery helps in prognosticating and counselling patients and relatives in the 
management of the disease. Quality of life assessment helps in understanding the 
patients’ perception of the disease and its treatment impact in a subjective way.  
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 To find the incidence of exocrine pancreatic insufficiency following 
gastrectomy, for gastric cancer. 
 
 To assess the quality of life in patients undergoing gastric resection for 
malignancy. 
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Anatomy of Stomach: 
 
 
During the fifth week of gestation, stomach begins as a dilation in the tubular embryonic 
foregut. It descends, rotates and further dilates by seventh week with a disproportionate 
elongation of greater curvature. Stomach connects the oesophagus to the duodenum and 
forms the most distensible part of gastrointestinal tract. The stomach is bounded 
superiorly by the diaphragm and laterally by the spleen. The most proximal part of 
stomach is the cardia which lies immediately distal to the physiologically competent 
lower oesophageal sphincter. Distally, the pylorus connected the distal stomach 
(antrum) to the first part of duodenum. The floppy and distensible fundus forms the 
superior most past of the stomach. Corpus or the body of the stomach is the largest 
portion of the stomach.  
 
Blood Supply 
 
The main blood supply of the stomach is from the coeliac artery. The left and the right 
gastric arteries run along the lesser curvature and left and right gastroepiploic arteries 
run along the greater curvature. In addition, proximal stomach is also supplied by the 
inferior phrenic arteries and short gastric arteries. The veins of the stomach usually 
parallel the arteries. The right gastric and left gastric (coronary) veins usually drain into 
the portal vein. The right gastroepiploic vein drains into the superior mesenteric vein 
and the left gastroepiploic veins drain into the splenic vein.  
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Lymphatic Drainage 
 
The lymphatic drainage parallels the vasculature of the stomach and drains into four 
zones of lymph nodes. The upper gastric curvature drains through the superior gastric 
group into the left gastric and paracardial nodes. The antral segment on the lesser 
curvature drains through the suprapyloric group of nodes into the right suprapancreatic 
nodes. The greater curvature of stomach drains into the left gastroepiploic and splenic 
nodes through the pancreaticolienal group of nodes. All the four group of lymph nodes 
drain into the celiac nodes and then into the thoracic duct. The extensive submucosal 
plexus of lymphatics is responsible for microscopic evidence of malignant cells several 
centimetres from the location of gross disease. 
Innervation 
 
The parasympathetic via the vagus and sympathetic via the celiac plexus forms the 
extrinsic innervation of the stomach. The neurons in Auerbach’s and Meissner’s 
autonomic plexus forms the enteric or intrinsic nervous system of stomach.    
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Outline of Gastric Carcinoma  
 
Epidemiology and Risk factors  
 
The second-most common cancer among men and third-most among females in Asia 
and worldwide is stomach cancer. The symptoms and signs of gastric malignancy often 
present late and the disease would already be advanced stage. In gastric malignancy,  5-
year survival is less than 30% in developed countries and around 20% in developing 
countries (1). One of the leading cause of cancer in south India is stomach cancer. Its 
incidence is decreasing globally. But on worldwide scale gastric cancer remains one of 
the most common causes of death due to cancer. Aetiology of stomach cancer 
includes Helicobacter pylori infection, diet and lifestyle, alcohol, tobacco and genetic 
susceptibility (2). About 8.6% of all cancers that occurred in 2002 were gastric cancer. 
The stomach cancer rates show significant geographical variation. High-risk areas 
include Japan, China, Eastern Europe and few countries in Latin America. Low-risk 
population is present among the white race in North America, India, Philippines, most 
countries in Africa, some Western European countries and Australia.(1) The number of 
new gastric cancer cases in 2001 was calculated to be  approximately 35,675 (n= 11,890 
in women; 23,785 in men).(3) These incidence rate differences can be accredited to 
multiple factors like differences in diet and cultural habits, and Helicobacter pylori 
infection. 
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Clinical presentation of Gastric carcinoma 
 
The symptoms of gastric cancer are usually vague and non-specific, with patients often 
presenting at an advanced stage. The common presenting complaints 
include dyspepsia, dysphagia, nausea, vomiting, melena, and hematemesis. Non-
specific cancer symptoms (anorexia, weight loss, or anaemia) are indicators of late stage 
disease. On examination, clinical signs are usually completely absent, especially in the 
early stages. In advanced disease, examination findings include evidence of jaundice, 
anaemia or hepatomegaly (indicating likely metastases to the liver), Troisier’s sign, or 
a palpable epigastric mass. 
 
Staging  
The most recent staging guidelines is 8th Edition of the AJCC Gastric Cancer Staging 
System(4,5) 
T category  
Table 1 T Category AJCC Gastric Cancer Staging System   
TX Primary tumour could not be assessed 
T0  No evidence of primary tumour 
Tis  Carcinoma in situ: intraepithelial tumour without invasion of the lamina 
propria 
T1  Tumour invades lamina propria, muscularis mucosae, or submucosa 
T1a  Tumour invades lamina propria or muscularis mucosae 
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T1b  Tumour invades submucosa 
T2  Tumour invades muscularis propria 
T3  
 
Tumour penetrates subserosal connective tissue without invasion of visceral 
peritoneum or adjacent structures. T3 tumours also include those extending 
into the gastrocolic or gastrohepatic ligaments, or into the greater or lesser 
omentum, without perforation of the visceral peritoneum covering these 
structures 
T4  Tumour invades serosa (visceral peritoneum) or adjacent structures 
T4a  Tumour invades serosa (visceral peritoneum) 
T4b  Tumour invades adjacent structures such as spleen, transverse colon, liver, 
diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, 
and retroperitoneum 
 
N category   
Table 2 N Category AJCC Gastric Cancer Staging System 
NX  Regional lymph node(s) cannot be assessed 
N0  No regional lymph node metastasis 
N1  Metastasis in 1 to 2 regional lymph nodes 
N2  Metastasis in 3 to 6 regional lymph nodes 
N3  Metastasis in 7 or more regional lymph nodes 
N3a  Metastasis in 7 – 15 regional lymph nodes 
N3b  Metastasis in 16 or more regional lymph nodes 
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M category   
M0       No distant metastasis  
M1       Distant metastasis 
Clinical staging 
 
Stage 0: Tis N0 M0  
Stage I: T1-2 N0 M0  
Stage IIA: T1-2 N1-3 M0  
Stage IIB: T3-4a N0 M0  
Stage III: T3-4a N1-3 M0  
Stage IVA: T4b N1-3 M0  
Stage IVB: any T any N M1  
 
 
 
Pathologic staging 
 
Stage 0: Tis N0 M0  
Stage IA: T1 N0 M0  
Stage IB: T1 N1 M0  
 T2 N0 M0  
Stage IIA: T1 N2 M0  
 T2 N1 M0  
 T3 N0 M0  
Stage IIB: T1 N3a M0  
 T2 N2 M0  
 T3 N1 M0  
 T4a N0 M0  
Stage IIIA: T2 N3a M0  
 T3 N2 M0  
 T4a N1-2 M0  
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 T4b N0 M0  
Stage IIIB: T1-2 N3b M0  
 T3-4a N3a M0  
 T4b N1-2 M0  
Stage IIIC: T3-4a N3b M0  
 T4b N3a-3b M0  
Stage IV: any T any N M1  
 
 
Pathologic staging following neoadjuvant therapy 
 
Stage I: T1-2 N0 M0  
 T1 N1 M0  
Stage II: T3-4a N0 M0  
 T2-3 N1 M0  
 T1-2 N2 M0  
 T1 N3 M0  
Stage III: T4b N0 M0  
 T4a-4b N1 M0  
 T3, 4a, 4b N2 M0  
 T2, 3, 4a, 4b N3 M0  
Stage IV: any T any N M1  
 
 Regional lymph nodes 
Greater curvature, greater omental, lesser curvature, lesser omental, right and 
left paracardial (cardioesophageal), suprapyloric, gastroduodenal, infrapyloric, 
gastroepiploic, left gastric artery, celiac artery, common hepatic artery, 
hepatoduodenal, portal, splenic artery, and splenic hilum nodes 
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 Non-regional (distant) lymph nodes  
Retropancreatic, pancreaticoduodenal, peripancreatic, superior mesenteric, 
middle colic, para-aortic, retroperitoneal, others 
Lymph Node Stations 
Table 3 Lymph Node Stations of Stomach 
Station Number Lymph Node 
1 Right cardiac nodes 
2 Left cardiac nodes 
3 Nodes along present the lesser curvature 
4 Nodes along present the greater curvature 
5 Suprapyloric nodes 
6 Infrapyloric nodes 
7 Nodes present along the left gastric artery 
8 Nodes present along the common hepatic artery 
9 Nodes present around the coeliac axis 
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10 Nodes seen at the splenic hilum 
11 Nodes present along the splenic artery 
12 Nodes present in the hepatoduodenal ligament 
13 Nodes at the posterior aspect of the head of pancreas 
14 Nodes present at the root of the mesentery 
15 Nodes present in the mesocolon of the transverse colon 
16 Para-aortic lymph nodes 
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LYMPH NODE STATIONS 
 
 
Figure 1 Numbering and location of lymph node stations 
Reproduced from “Gastric Cancer: current status of lymph node dissection”., World J 
Gastroenterol 2016 March 14; 22(10):2875 - 2893(6) 
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Management of Gastric carcinoma  
 
Surgical resection of tumour with adequate margins and adequate lymphadenectomy 
gives the brightest chance of survival for patients with gastric cancer. Total or subtotal 
gastrectomy are the primary surgical options available. Endoscopic management is a 
treatment option in case of early disease.   
Theodor Billroth performed the first successful partial or subtotal gastrectomy in 1881.  
End to end gastroduodenal anastomosis formed the reconstruction. This success was 
attained only thorough research and studies on the anatomy of the stomach and its 
physiology. It involved multiple rehearsals on animal models.  This surgery had been 
called as the Billroth I gastrectomy. Woelfler – a pupil of Billroth- in 1881 performed 
first successful gastro-jejunal anastomosis on a patient with an unresectable pyloric 
region carcinoma.  Woelfler performed the first ‘anastomosis-en-Y’ in 1883 to prevent 
kinking of the jejunal loop that led to death from persistent biliary vomiting in few 
cases. This operative method was popularised by Roux of Lausanne and was called 
Roux en Y anastomosis hence. The first subtotal gastrectomy with gastrojejunostomy 
was done at Billroth’s clinic by Von Hacker in 1885, on a debilitated patient who had a 
large, but mobile carcinoma of the pylorus. It was performed as a staged procedure. A 
loop of jejunum was first anastomosed to the stomach, proximal to the growth. Once 
the anastomosis began to function, the second operation comprising a partial 
gastrectomy was carried out with closure of the gastric and duodenal stumps. This 
procedure was named as the Billroth II partial gastrectomy.   
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In the following years, multiple modifications were applied to the described procedures 
and identification of pitfalls and complications of each type.  In 1897, Schlatter 
performed the first successful total gastrectomy with an oesophago-jejunal anastomosis. 
By 19th century, gastrectomies became outspread for the management of stomach 
cancer. As days progressed, many surgeons became proficient with the operation and 
eventually fell mortality rates associated with the procedure.   
Neoadjuvant therapy and adjuvant therapy would include chemotherapy and 
radiotherapy as indicated based on tumour pathology, stage of the disease, 
histopathology of resection specimen and patient health status. Efforts to improve 
treatment results beyond those obtained with surgery alone have included adjuvant 
(postoperative) and neoadjuvant (preoperative) strategies. The positive impact of such 
therapies on survival in patients with resected gastric cancer has become clearer over 
time, although there is no consensus as to the best approach. 
 
Gastrectomy and reconstruction methods 
 
Gastrectomy is defined as the surgical procedure which involves removal of all or part 
of the stomach. The two most common types of gastrectomy are subtotal gastrectomy 
and total gastrectomy.  In total gastrectomy, the whole stomach is removed and in partial 
gastrectomy, the lower part of the stomach is removed. The location of the tumour 
decides the extent of gastrectomy when done for a curative intend. (7) After a distal 
stomach resection, the continuity of the digestive tract can be re-established by either 
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Billroth I (gastro duodenal anastomosis), Billroth II (gastrojejunal anastomosis) or a 
Roux-en-Y gastrojejunostomy. When gastric resection is done for malignancy, the 
commonest type of reconstruction here in our institute is by the Roux en Y technique. 
(8). This reconstruction alters the normal passage of food through the duodenum and 
creates an alternative path. 
 
 
 
Reconstruction methods following gastrectomy 
 
 
Figure 2 Gastrectomy Reconstruction Methods 
Reproduced from Gastric cancer, June 2015 (9) 
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Functional Anatomy of Pancreas 
 
 
Pancreas functions to synthesize and secrete digestive enzymes into the gastrointestinal 
tract and also synthesize and secrete hormones into the blood which in turn controls the 
energy storage and metabolism in the body. Exocrine pancreas comprises more than 
95% pancreatic mass which includes acinar and duct cells with associated connective 
tissue, vessels, and nerves. This part of pancreas synthesizes and secretes digestive 
enzymes into the duodenum. Islets that make up 1-2 % of pancreatic mass synthesizes 
and secrete insulin, glucagon, somatostatin and pancreatic polypeptide into the blood.  
 
In the C loop of the duodenum lies the head of the pancreas. Near the hilum of the spleen 
lies the tail of pancreas.  Lying posterior to the distal portion of the stomach between 
the tail and the neck is the body of the pancreas. The pancreas is supplied by the 
pancreatic branches of the splenic artery. The head is also supplied by the branches of 
gastroduodenal and superior mesenteric artery. Most of the arteries supplying the 
pancreas are accompanied by veins which drain into the portal and splenic veins. The 
superior mesenteric vein joins the splenic vein to form the portal vein.  
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Clinical features of malabsorption in patients following 
gastrectomy  
 
Steatorrhea is defined as frothy, foul smelling, buoyant stools. Steatorrhea, abdominal 
discomfort, weight loss and abdominal bloating are the common presenting complaints 
in cases of fat malabsorption. Carbohydrate and protein digestion are sustained at 
normal physiologic levels even in cases of significant exocrine pancreatic insufficiency. 
But, once exocrine pancreatic insufficiency progresses, fat malabsorption becomes the 
predominant issue and causes the clinical symptoms of lipid malabsorption and also 
cause nutritional deficiencies. Symptoms such as diarrhoea, steatorrhea, flatulence, loss 
of appetite, and increased bowel movements occurring most often in combination with 
each other may finally result in malnutrition and weight loss(10,11). Several hypotheses 
have been proposed to explain gastrointestinal symptoms following gastric resection, 
such as bacterial colonization of the duodenum, low-calorie intake due to changed 
eating habits, pancreatic insufficiency due to a loss of stimulation of the pancreas, and 
a rapid upper intestinal transit time(11,12). Frequently observed symptoms such as 
diarrhoea and steatorrhea have all been described in relation to pancreatic 
insufficiency(13). Loss of gastric pancreatic innervation and the loss of release of 
hormones like cholecystokinin are hypothesized to affect the pancreatic function. 
Whether these theories, solely or in combination, may attribute to a decreased exocrine 
function of the pancreas is yet to be determined(14) 
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As stated, many patients suffer from gastrointestinal symptoms. It is unclear how many 
patients are affected by exocrine pancreatic insufficiency after gastrectomy and whether 
these patients could benefit from supplementary therapy. 
Malnutrition is a consequence of abnormal fat digestion. This in turn leads to 
malabsorption of fat-soluble vitamins. Also seen are decreased circulating lipoproteins 
and decreased micronutrients (15–17). Issues with mixing of digestive enzymes or 
problems with digestive mediators cause problems with digestion. This includes 
patients post gastric resection and patients with insufficiency of intestinal enzymes or 
pancreatic enzymes, or  bile salts(18). 
 
Exocrine Pancreatic Insufficiency 
 
Exocrine Pancreatic Insufficiency is defined as decrease in pancreatic enzyme activity 
in the lumen of intestine to levels below the threshold needed for normal digestion. This 
problem is seen usually in resections of stomach and pancreas. Insufficient enzyme 
production, insufficient enzyme activation or disturbed enzyme deactivation causes the 
inadequate pancreatic enzyme activity causing this problem. Fundus relaxation, antral 
motility and the pylorus motor activity regulate the gastric emptying of nutrients. These 
functions are tightly regulated by antro-fundic reflexes (fundus relaxation secondary to 
the presence of nutrients in the gastric antrum) and duodenogastric reflexes. Post-
prandial pancreatic secretion is first neurally stimulated by fundus relaxation, which 
triggers a vagal reflex (neurally mediated post-prandial stimulation of exocrine 
pancreatic secretion). Thereafter, the release of cholecystokinin (CCK) in response to 
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the nutrient-stimulated duodenal secretion of CCK-releasing peptide represents the 
major hormone-mediated post-prandial stimulation of exocrine pancreatic secretion. In 
gastrectomy patients, the following changes occur which can cause a change in 
pancreatic secretion 
(i) Disturbance of fundus relaxation caused by the disappearance of antro-fundic 
and duodeno-fundic reflexes; 
(ii) Absence of neurally stimulated pancreatic secretion caused by the lack of fundus 
relaxation;  
(iii) Reduction in CCK- mediated stimulation of pancreatic secretion secondary to 
duodenal bypass;  
(iv) Large and hard-to-digest nutrient particles reaching the jejunal lumen because 
of resection of the distal stomach;  
(v) Asynchrony between the gastric emptying of nutrients and bilio-pancreatic 
secretion as a result of anatomical reconstruction(19).  
Further, since vagotomy is inherent in gastrectomy, any coincident denervation of the 
pancreas may alter its response to food after operation.  
In 1996, Friess et al (20) demonstrated that 100% of patients develop severe primary 
exocrine pancreatic insufficiency three months after a total gastrectomy. Chymotrypsin 
and trypsin were the most severely deficient enzymes after gastric surgery, with a 
decreased production of up to 91% three months after surgery. Low levels of gastrin 
and postprandial pancreatic polypeptides, and high levels of cholecystokinin were also 
reported (20). Exocrine pancreatic insufficiency is reported in both total and partial 
gastrectomy.  Büchler et al (21) demonstrated that the pancreolauryl test was 
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pathological in 47%- 64% of patients after Billroth-I surgery and in 64%-70% after 
Billroth-II surgery. On the contrary, Heptner et al (22) reported EPI after gastric 
resection in only 30% of patients, even if the pancreolauryl test was abnormal in 90% 
of these patients.  
Exocrine pancreatic insufficiency as a cause for gastrointestinal symptoms post-
gastrectomy was examined by 2 studies. Both prospective studies used the decrease in 
excretion of exocrine pancreatic enzymes such as chymotrypsin, lipase, and bicarbonate 
as a measure for exocrine pancreatic insufficiency; Gullo et al. (23) compared 
pancreatic secretion of patients who underwent gastrectomy with controls in contrast to 
Friess et al. (20) who measured pre- and postoperative pancreatic secretion in 
gastrectomy patients. Gullo et al. (23) found a mean decrease in bicarbonate, lipase, and 
chymotrypsin of 47.9, 38.7, and 24.2% in 12 patients respectively. A stimulation test 
with secretin and cerulein did not produce any additional increase. Eight out of 12 
patients had a measured faecal fat excretion over 7 g/24 h. No significant correlation 
between faecal fat excretion and lipase excretion was found (23) . The stimulation test 
with secretin and cerulein resulted in the study of Friess et al.(20) in a mean decrease 
of 92% of bicarbonate ( p  < 0.01), 47% amylase ( p  < 0.05), and 91% chymotrypsin ( 
p  < 0.01) in 15 patients. The total amount of pancreatic secretion was after secretin and 
cerulein stimulation decreased with 76% (p < 0.01). Gastrectomy did not only influence 
the pancreatic enzyme output; gastrointestinal hormone blood levels were also altered. 
Gastrin levels were significantly reduced by 43%, and pancreatic polypeptide (PP) 
levels were decreased by 61%. Three months later, PP was still reduced by 42% in 
comparison to preoperative levels.  
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Pancreatic Enzyme Supplementation 
 
There were two studies which were done specifically to assess the effects of enzyme 
supplementation on the gastro-intestinal symptoms in patients with exocrine pancreatic 
insufficiency following total gastrectomy (24,25) one of which was a randomized 
controlled trial and the other being a crossover trial. Armbrecht et al.(24) performed a 
double blind crossover study with a sample size of 15 patients in which every patient 
had a  7 day intervention period, followed by or  preceded by a 7 day long placebo 
period. There was a statistically significant association between that the stool 
consistency and enzyme supplementation in patients after total gastrectomy (p < 0.05). 
Another parameter which was assessed was the median faecal fat excretion, in patients 
with high-degree steatorrhea reduced significantly from 643 to 501 mmol/72 h (p < 
0.05). The degree to which the steatorrhea of the total group did not decline significantly 
after pancreatic enzyme supplement (Kreon) substitution. The 5 symptoms which were 
used to assess the quality of life – bloating, nausea, vomiting, dumping and pain – did 
not change in a significant manner. Brägelmann et al.(25) had done a  prospective 
parallel, randomized, placebo-controlled, double blind trial on pancreatic enzyme 
supplementation after total gastrectomy on 52 patients. Similar symptoms as the 
previous study – dyspepsia, bloating, early satiety, reflux, and postprandial vomiting 
were assessed, which revealed that in the enzyme-treated group had a significant 
improvement in the quality of life (p = 0.006) in comparison with the placebo group,  
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In a study done Huddy et al. found that exocrine pancreatic insufficiency contributes to 
postoperative morbidity after an esophagectomy, and that these patients can potentially 
be benefitted from  enzyme supplementation (26).  
 
The exocrine pancreatic enzyme is individual dependent, therefore pancreatic 
insufficiency is a clinical diagnosis and the treatment is based on patient 
symptomatology as mentioned earlier (27).  
The gold standard accepted worldwide is the 72-h faecal fat collection, expressed as the 
coefficient of fat absorption (13,28) which is a non-invasive method to assess pancreatic 
enzyme deficiency, the other method being using a upper gastrointestinal (GI) scopy to 
suck out duodenal secretions .Both these measurements are done to accurately correlate 
the amount of dysfunction of the pancreas to the effect of enzyme supplementation. 
There are multiple studies which state that a fall to 10% of the normal exocrine 
pancreatic secretions causes symptoms. 
There have been much more recent randomised control studies in patients having 
chronic pancreatitis or following pancreatic surgery with documented exocrine 
pancreatic insufficiency, showing benefit following enzyme supplementation (29) .  
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Tests of pancreatic function 
Pancreatic function tests are required to confirm the diagnosis of exocrine pancreatic 
insufficiency. Estimation of 72-hour stool fat level is a cumbersome process for the 
patient and required admission for testing.  Tests of pancreatic exocrine function can be 
direct or indirect. Though direct pancreatic function tests are considered most sensitive 
diagnostic tests for exocrine pancreatic insufficiency, they are not easily available in 
India. Direct tests include involve stimulation of the pancreas by administration of 
hormonal secretagogues after which endoscopy is done and duodenal fluid is collected 
which is analysed to directly quantify pancreatic secretory content. The secretory 
content includes enzymes and bicarbonate. Major drawback of direct testing methods 
is the lack of expertise and poor patient tolerance. Also invasive tests such as endoscopy 
are not well tolerated by patients in the post-operative period. Available direct tests are 
the secretin stimulation test, the Lundh test meal, and measurement of serum or faecal 
enzymes.  The secretin stimulation test requires duodenal intubation to collect duodenal 
fluid for assessment of bicarbonate concentrations.  Indirect pancreatic exocrine 
function tests work by measuring the effect of pancreatic secretion on various enzymes 
or nutrients. Indirect tests measure the consequence of exocrine insufficiency 
(maldigestion). These include triglycerides labelled with carbon 14, cobalamin labelled 
with cobalt 57 and cobalt 58, faecal elastase 1, faecal chymotrypsin and serum 
trypsinogen.  The indirect tests are simpler to do and appear to be comparable to the 
secretin test at detecting pancreatic exocrine insufficiency. 
45 
 
Stool Elastase – ELISA 
 
Pancreatic elastase-1 is a specific human protease synthetized by the acinar cells. 
Pancreatic stool elastase is an enzyme linked immunosorbent assay (ELISA) for the 
quantitative determination of human pancreatic elastase in faeces as an aid in the 
diagnosis of the exocrine pancreatic function. Pancreatic elastase is a proteolytic 
enzyme exclusively produced in pancreas. This is a sensitive, specific, and relatively 
inexpensive non-invasive test. It is an accurate function test for patients with chronic 
pancreatitis confirmed by endoscopic retrograde cholangiopancreatography and 
computerized axial tomography. The enzyme stability is remarkably high during the 
intestinal passage and is even accumulated in a six-fold concentration in stool, 
compared to the concentration in the duodenal juice. This assay uses polyclonal 
antibodies that are specifically directed against defined peptide sequences of the human 
pancreatic elastase molecule. These sequences are species and organ specific. (30) For 
the assessment of pancreatic function, literature has showed that faecal pancreatic 
elastase  suitable replacement to faecal fat analysis.(31) It shows higher sensitivity and 
specificity for exocrine pancreatic insufficiency than faecal chymotrypsin 
determination and is comparable to oral pancreatic function tests such as the 
pancreolauryl test(32) Faecal elastase test is unaffected by gastric resection.(33) Hence 
can be used in post-operative patients following gastrectomy. 
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Principles of the Assay Method  
 
The Pancreatic Elastase ELISA (Enzyme Linked Immunosorbent Assay) from 
BIOSERV Diagnostics is a solid-phase enzyme-linked immunosorbent assay based on 
a double-sandwich technique for the quantitative determination of human pancreatic 
elastase in faeces. Two polyclonal antibodies are recognizing several different epitopes 
on defined species- and organ-specific human pancreatic elastase peptide sequences. 
BIOSERV Diagnostics is using polyclonal antibodies which recognize several different 
epitopes in parallel to reach a higher diagnostic sensitivity and specificity. The ELISA 
microplate is coated with antibodies directed against human pancreatic elastase binding 
the pancreatic elastase contained in the patient samples or in the standards, respectively. 
In the following step the second antibody, labelled with biotin, binds to the immobilized 
pancreatic elastase. To visualize the bound pancreatic elastase, the biotin binds in the 
following step to streptavidin labelled horseradish-peroxidase. The peroxidase then 
oxidizes the substrate TMB (3,3’,5,5’- tetra methyl benzidine). The reaction will be 
stopped by addition of 0.25 mol/l H2SO4. The developed dye (oxidized TMB) can be 
measured photo metrically at 450 nm. A reference measurement using a reference filter 
at ≥ 550 nm wavelength is recommended but not mandatory. 
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Sample Type: Faeces. 
 
Samples can be stored at different temperatures for the following time-spans: 
Environmental temperature up to 40 °C for up to five days, 
 Refrigerator temperature (2 °C – 8 °C) for up to one week and 
 freezer temperature (-18 °C – -20 °C) for up to one year. 
 For liquid stool sample either collect another sample with a more solid consistency or, 
if this is not possible, heat the watery stool sample in a water bath to 55 °C (131 °F), at 
which temperature the elastase does not denature and concentrate the sample until it 
reaches normal stool consistency.  
 
Interpretative criteria:  
< 100 μg elastase/g faeces = severe exocrine pancreatic insufficiency 
100 - 200 μg elastase/g faeces = moderate exocrine pancreatic insufficiency 
> 200 μg elastase/g faeces = normal exocrine pancreatic function 
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Assay Performance characteristics:(34) 
With a cut off of 200 micrograms elastase 1/g stool the sensitivity was 63% for mild, 
100% for moderate, 100% for severe, and 93% for all patients with exocrine pancreatic 
insufficiency, and specificity was 93%. Values for chymotrypsin were 64% (sensitivity) 
and 89% (specificity). Significant (p<0.001) correlations were found for faecal and 
duodenal elastase with duodenal lipase, amylase, trypsin, volume, and bicarbonate 
output(35). Individual day to day variations of faecal elastase 1 concentrations were 
very low. 
 
Limitations of the Assay  
 At temperatures higher than 40 °C (104 °F) the samples should be transported 
cooled or refrigerated.  
 Watery faeces from patients with diarrhoea may lead to falsely low readings 
because of a dilution effect. 
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Quality of Life Assessment following Gastrectomy 
 
Although the long-term survival of patients with gastric cancer has improved due to earlier 
diagnosis and advances in multimodality management, significant morbidity associated with 
gastric resection remains. Patients may suffer from a variety of symptoms including early 
satiety, loss of appetite, heartburn, dysphagia, nausea and vomiting. These symptoms have a 
profound impact on patients’ health-related quality of life (QOL)(36). Quality of life tools are 
essential to find out about the subjective effect of disease and its management as felt by 
patients.(37) Quality of Life Assessment The EORTCQLQ-C30 is a reliable and validated 
measure of the quality of life of cancer patients in multicultural clinical research. The 
questionnaire is a cancer-specific, self-administered, structured questionnaire that contains 30 
questions, 24 of which form nine multi-item scales representing various aspects, or dimensions, 
of QOL: one global scale, five functional scales (Physical, Role, Emotional, Cognitive and 
Social), and three symptom scales (Fatigue, Pain and Nausea). The remaining 6 items are 
mono-item scales describing relevant cancer oriented symptoms (dyspnoea, insomnia, appetite, 
constipation, diarrhoea, financial difficulties). The gastric cancer module (QLQ-STO22) is a 
supplement to the QLQ-C30 intended for patients at all disease stages undergoing surgical 
resection, palliative surgical intervention, endoscopic palliation or palliative chemotherapy. 
The QLQ-STO22 consists of 22 questions which evaluate five multi-item symptoms scales 
(dysphagia, eating restrictions, pain, reflux and anxiety), and four single item symptoms scales 
(dry mouth, body image, hair loss and taste loss). For Global QOL and the functional scales, a 
higher score indicates better QOL, with 100 being perfect. For symptom scales, a lower score 
indicates better QOL, with 0 being perfect or no symptoms reported(38,39). We were interested 
in the dysphagia, eating restrictions, pain, reflux symptoms and the overall quality of life 
among our patients in the semi structured questionnaire. 
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MATERIALS AND 
METHODS 
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Setting 
 
This study was conducted in the Upper GI surgical unit, Department of General Surgery 
at Christian Medical College, Vellore. The study included patients undergoing gastric 
resection for gastric malignancy in the Upper GI surgical unit. This study methodology 
was approved by the Institutional review board on 7/1/2017 and recruitment started on 
7/1/2017 and was completed on 30/9/2018.  
The protocol followed for evaluation and management of patients with gastric 
adenocarcinoma were as follows. Patients present either to General Surgery OPD for 
evaluation of symptoms or as a referral from primary centres or present acutely to 
Accident and Emergency Services with features of gastric outlet obstruction or bleeding 
gastric cancer. After evaluation with necessary diagnostic investigations, each patient 
is discussed at Multidisciplinary tumour board meeting which involves consultants from 
departments of Radiology, Upper Gastrointestinal Surgery, Radiotherapy, Medical 
Oncology and Pathology, along with an Upper GI specialist nurse. Based on tumour 
staging, patient symptomatology, patient health and comorbid profile, a decision is 
made on neoadjuvant therapy or upfront surgery.   
Patients fulfilling the criteria for recruitment in the study were consented and included 
in the study. Patients were recruited in General Surgery OPD before admission for 
surgery. They were followed up in the ward during surgery and were reviewed back in 
General Surgery OPD post-operatively after discharge. 
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Exocrine Pancreatic Insufficiency following Gastrectomy: 
This was the prospective arm of the study. Continuous sampling of all patients 
undergoing gastrectomy for gastric cancer till sample size is reached in each group 
(subtotal and total gastrectomy). Pre-operative stool elastase was tested. At a follow up 
OPD visit any time after the patient starts taking a normal diet, post-operative stool 
elastase was tested. 
Participants 
Inclusion criteria: 
Among the patients planned for gastrectomy, those fulfilling the below criteria were included 
in the study. 
• Should undergo gastrectomy (total or subtotal) for gastric adenocarcinoma with Roux 
en Y reconstruction.  
• Should be on normal diet at the time of postoperative stool elastase testing.  
 
Exclusion criteria: 
 History of diabetes 
 Stool elastase value less than normal on preoperative analysis 
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Flowchart of Patient Recruitment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients planned for gastrectomy for gastric malignancy 
Inclusion and exclusion criteria applied 
Included and consented patients Excluded patients 
Subtotal Gastrectomy 
(Continuous sampling till sample 
size is reached) 
Total Gastrectomy 
(Continuous sampling of one 
year / 10 patients) 
 
Stool Elastase test- Pre op 
 
Stool Elastase test- Pre op 
 
Surgery Surgery 
 
Stool Elastase test- Post op 
 
Stool Elastase test- Post op 
 
All patients who underwent gastrectomy for gastric adenocarcinoma in the past 4 years in Upper 
GI Surgery department would be consented and administered the quality of life questionnaire by 
principal investigator in OPD and/or by mail and/or email and/or phone 
Post-operative routine follow 
-up OPD visit 
Quality of life questionnaire to 
be filled 
Quality of life questionnaire to be 
filled 
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Quality of Life following resection for Gastric adenocarcinoma: 
This analysis included both prospective and retrospective components. All patients who 
underwent gastrectomy for adenocarcinoma stomach during the study period in 2017 
were assessed for quality of life during their postoperative period. Retrospective QOL 
analysis was performed on the patients who had undergone gastrectomy for 
adenocarcinoma stomach between the years 2013 and 2016. They were contacted when 
they presented to the OPD for review and/or through post and/or phone and/or email 
for administering quality of life questionnaire. 
 
Data Sources/measurement:  
All the variables in data collection sheet were obtained from the medical records of patients 
consented and recruited in the study. Clinical workstation was used to obtain the necessary 
clinical information and biochemical test results of the patient. Stool elastase testing was done 
in Wellcome Biochemistry laboratory in CMC Hospital, Vellore.  
All the variables for quality of life assessment were obtained from the patient by a self-
administered/ interviewer administered semi structured questionnaire from a validated 
questionnaire EORTC QLQ C30 and EORTC QLQ STO22. Internal validity was checked from 
the study. Consent for using the EORTC questionnaire was obtained from EORTC. 
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Sample size calculation 
 
Sample size for exocrine pancreatic insufficiency was calculated for two groups (Sub-total and 
Total) Gastrectomy separately based on available literature.  
Subtotal gastrectomy  
 
Expected  Proportion 0.697 
Precision (%) 14 
Desired confidence level  (1- alpha) % 95 
Required sample size 42 
 
With reference to Langenbecks Arch Chir. 1985;367(21):41-50 ,EPI found among post 
gastrectomy patient with BII reconstruction was found to be 69.7, with a relative precision(20% 
of proportion) at 14% and a desired confidence interval at 95% we need to study 42 sub-total 
gastrectomy patients. 
 
Total gastrectomy  
 
With reference to AmJ Gastroenterol. 1996 Feb;91(20):341-7.,EPI found among post total 
gastrectomy patient was found to be 100%. The total number of total gastrectomy operations 
in a year is around 10 -12. Hence all the total gastrectomy patients in one year would be taken 
for finding out the prevalence of exocrine pancreas insufficiency following total gastrectomy. 
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Estimating single Proportion (Relative precision) Reference Lemeshow S, Hosmer DW, Klar 
J, Lwanga SK.Adequacy of Sample Size in Health Studies. John Wiley and Sons, 1990(40) 
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IRB and Ethics committee approval 
 
This study protocol was reviewed and approved by the Institutional Review Board, Christian 
Medical College, Vellore on 7/1/2017.   
 
Informed Consent 
 
All patients included in the study were explained the objectives of the study and were supplied 
with information sheet containing the necessary information regarding the study. All the 
included patients signed a written consent for their participation in the study.  
 
Data analysis and statistical methods 
Collected data was entered using Epidata® 3.1. Data analysis was done using SPSS software 
(IBN Corporation®. Released 2015. IBN SPSS Statistics for Windows, Version 23.0. 
Armonk, NY: IBN Corp.). Bibliography was managed used Zotero® (Centre at George 
Mason University). Descriptive statistics were reported using Mean +/- SD. Frequency and 
percentage were reported for categorical variables. Chi square/ Fisher’s exact test were done 
to check the association between the categorical variables and the outcome variable. Student T 
test was used for comparing two continuous compare variables. P value <0.05 was considered 
as statistically significant. ANOVA (Analysis of variance) was used to compare three or more 
continuous variables.  
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RESULTS 
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Exocrine Pancreatic insufficiency following Gastrectomy 
Recruitment details: 
 
    Figure 3 Case Recruitment Distribution 
 
45 patients were recruited in the subtotal gastrectomy group and 15 patients were 
recruited in the total gastrectomy group. 
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SUB-TOTAL GASTRECTOMY 
Number of patients recruited = 45 
 
 
Age Distribution
 
Figure 4 Age Distribution - Subtotal gastrectomy 
Most patients were in the age group between 51 and 60. The mean age was 52. The 
lowest age seen in the group was 30 and the highest was 78. 
  
1
5
13
17
8
1
0
2
4
6
8
10
12
14
16
18
21-30 31-40 41-50 51-60 61-70 >71
N
o
. o
f 
P
at
ie
n
ts
Age group
61 
 
 
 
Gender Distribution
 
Figure 5 Gender Distribution Subtotal gastrectomy 
 
Among the 45 patients included in the study who underwent sub-total gastrectomy, 33 
were male and 12 were female. 
 
 
  
33, 73%
12, 27%
N=45
Male Female
62 
 
Regional Distribution 
 
Table 4 Regional Distribution Subtotal Gastrectomy 
Locality Number of patients Percentage 
Andhra Pradesh  3 6.6 
Assam  2 4.4 
Jharkhand 8 17.8 
Orissa  1 2.2 
Sikkim 1 2.2 
Tamil Nadu 13 28.9 
West Bengal 7 15.6 
Bangladesh  9 20 
Nepal 1 2.2 
Total 45 100 
 
Majority of the patients were from Tamil Nadu followed by patients from Bangladesh 
and then Jharkhand. There was 1 patient from Nepal also. 
 
 
Method of Surgery 
 
Table 5 Method of surgery Subtotal Gastrectomy 
Method Number of patients Percentage 
Laparoscopic  2 4.4 
Open 43 95.6 
 
Among the 45 patients, 43 underwent open subtotal gastrectomy and 2 patients 
underwent totally laparoscopic subtotal gastrectomy. There were no cases of 
laparoscopy assisted gastrectomy. 
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Resection Intent 
 
Table 6 Resection Intent Subtotal Gastrectomy 
Resection Intent Number of patients Percentage 
Palliative 5 11.1 
Curative 40 88.9 
 
5 patients underwent palliative R2 resection. 40 patients underwent curative (R0 or R1) 
resection. 
 
 
Lymphadenectomy 
 
Table 7 Extent of lymphadenectomy Subtotal Gastrectomy 
Lymphadenectomy Number of patients Percentage 
D1 5 11.1 
D1+ 5 11.1 
D2 35 77.8 
 
5 patients underwent D1 resection, 5 patients underwent D1+ resection and 35 patients 
underwent D2 resection. 
Type of anastomosis 
 
Table 8 Anastomosis type Subtotal Gastrectomy 
Anastomosis Type Number of patients Percentage 
Hand sewn 36 80 
Stapled 9 20 
 
36 patients underwent hand-sewn gastrojejunal anastomosis. Rest 9 patients in the study 
underwent stapled anastomosis. 
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Number of patients who were diagnosed to have an anastomotic leak = 7 (n=45).  
This included patients who had gastrojejunal anastomotic leak, jejunojejunal 
anastomotic leak and duodenal stump blow-out.     The rate of anastomotic leak was 
15.6 %  
 
Number of patients who were re-operated for anastomotic leak = 6 (n=45). The 
reoperation rate among sub-total gastrectomy patients included in the study was 13.3 % 
There were no other causes of re-operation seen in this group of patients. 
 
35 patients had upfront surgery for gastric adenocarcinoma. 10 patients had neoadjuvant 
chemotherapy. 27 patients had only adjuvant chemotherapy. 11 patients had adjuvant 
radiotherapy.  
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Comorbidities 
 
 
Figure 6 Distribution of Comorbidities Subtotal gastrectomy 
 
Hypertension was the most common comorbidity seen in this group of patients included 
in the study. There were no diabetics in the study since diabetes was a part of exclusion 
criteria for the study. 
 
Tumour Differentiation 
Table 9 Tumour Differentiation Subtotal Gastrectomy 
Tumour 
Differentiation 
 
Number of patients Percentage 
Well-differentiated 0 0 
Moderately 
differentiated 
21 46.7 
Poorly differentiated 24 53.3 
 
24 patients in the study had poorly differentiated tumour and 21 had moderately 
differentiated tumour. There were no cases of well-differentiated tumour. 
5
1 1
3 3
0
1
2
3
4
5
6
Hypertension Asthma COPD Thyroid Disorder CAD
N
u
m
b
er
 o
f 
p
at
ie
n
ts
Comorbid conditions
66 
 
 
TNM Staging 
Preoperative staging of the disease was considered for the study. The staging was based 
on radiological and pathological staging. In the case of upfront surgery, pathological 
grading of the disease was done. In patients who received neoadjuvant therapy, staging 
was done based on imaging done before initiation of neoadjuvant therapy.  
 
T Stage 
Table 10 T Stage Distribution Subtotal Gastrectomy 
 T Stage 
 
Number of patients Percentage 
T1 2 4.4 
T2 3 6.7 
T3 20 44.4 
T4 20 44.4 
 
 
N Stage 
 
Table 11 N Stage Distribution Subtotal Gastrectomy 
N Stage 
 
Number of patients Percentage 
N0 6 13.3 
N1 13 28.9 
N2 6 13.3 
N3 20 44.5 
 
Majority of the patients had N3 disease followed by N1 disease.  
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M Stage 
 
Table 12 M Stage Distribution Subtotal Gastrectomy 
 M Stage 
 
Number of patients Percentage 
M0 44 97.8 
M1 1 2.2 
 
Only one patient had metastatic disease in this group. 
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Exocrine pancreatic deficiency following Sub-total gastrectomy 
 
Number of patients who completed the stool elastase analysis = 34 
Analysis was considered completed when the recruited patients were followed up post-
operatively in the Surgery OPD and underwent post-operative stool elastase testing. 
Thirty-four patients completed the analysis. However, 14 patients had less than normal 
stool elastase preoperatively and hence were excluded.  
 
Using <200 μg elastase/g faeces as exocrine pancreatic deficiency cut-off: 
 
Number of patients who were included for analysis (had normal stool elastase 
preoperatively) = 20.  
 
Out of these 20 patients included, 8 patients were found to have abnormally low stool 
elastase post-operatively. 
 
Incidence of exocrine pancreatic deficiency following sub-total gastrectomy using 
stool elastase = 40% 
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TOTAL GASTRECTOMY 
 
Number of patients recruited = 15 
 
 
Age Distribution 
 
 
Figure 7 Age Distribution Total Gastrectomy 
 
Most patients were in the age group between 51 and 60. The mean age was 51. The 
lowest age seen in the group was 32 and the highest was 62. 
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Gender Distribution 
 
 
Figure 8 Gender Distribution Total Gastrectomy 
 
 
Among the 15 patients included in the study who underwent total gastrectomy, 6 were 
male and 9 were female. 
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71 
 
Regional Distribution 
 
Table 13 Regional Distribution Total Gastrectomy 
Locality Number of patients Percentage 
Bihar 1 6.7 
Chhattisgarh 1 6.7 
Jharkhand 2 13.3 
Mizoram 1 6.7 
Tamil Nadu 2 13.4 
West Bengal 3 20 
Bangladesh  5 33.3 
Total 15 100 
 
Most patients were from Bangladesh followed by West Bengal and Tamil Nadu. 
 
Method of Surgery 
 
Table 14 Method of surgery Total Gastrectomy 
Method Number of patients Percentage 
Laparoscopic  3 20 
Open 11 70.3 
Laparoscopy assisted 1 6.7 
 
Majority of patients (11 patients) underwent open gastrectomy. 3 patients underwent 
totally laparoscopic surgery and one patient underwent laparoscopy assisted surgery. 
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Resection Intent 
 
Table 15 Resection Intent Total Gastrectomy 
Resection Intent Number of patients Percentage 
Palliative 1 6.7 
Curative 14 93.3 
 
1 patient underwent palliative R2 resection. 14 patients underwent curative (R0 or R1) 
resection. 
 
 
Lymphadenectomy 
 
Table 16 Extent of Lymphadenectomy Total Gastrectomy 
Lymphadenectomy Number of patients Percentage 
D1 1 6.7 
D1+ 2 13.3 
D2 12 80 
 
1 patient underwent D1 resection, 2 patients underwent D1+ resection and 12 patients 
underwent D2 resection. 
 
Type of anastomosis 
Table 17 Type of anastomosis  Total Gastrectomy 
Anastomosis Type Number of patients Percentage 
Hand sewn 6 40 
Stapled 9 60 
 
6 patients underwent hand-sewn gastrojejunal anastomosis. Rest 9 patients in the study 
underwent stapled anastomosis.  
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Anastomotic leak was seen in 3 patients.  The rate of anastomotic leak was 20 % 
Number of patients who were re-operated for anastomotic leak was 2 (n=15). The 
reoperation rate among total gastrectomy patients included in the study was 13.3 % 
There were no other causes of re-operation seen in this group of patients. 
 
4 patients had upfront surgery for gastric adenocarcinoma. 11 patients had neoadjuvant 
chemotherapy. 3 patients had only adjuvant chemotherapy. 2 patients had adjuvant 
radiotherapy.  
 
Comorbidities 
 
 
Figure 9 Distribution of comorbidities Total Gastrectomy 
 
 
Most patients in this group had thyroid disorder. There were no diabetics in the study 
since diabetes was a part of exclusion criteria for the study. 
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Tumour Differentiation 
 
Table 18 Tumour Differentiation Total Gastrectomy 
Tumour 
Differentiation 
 
Number of patients Percentage 
Well-differentiated 0 0 
Moderately 
differentiated 
2 13.3 
Poorly differentiated 13 86.7 
 
Majority of the patients (86.7 %) had poorly differentiated tumour and rest had 
moderately differentiated tumour. None had well-differentiated tumour. 
 
T Stage 
 
Table 19 T Stage Distribution Total Gastrectomy 
 T Stage 
 
Number of patients Percentage 
T1 0 0 
T2 0 0 
T3 9 60 
T4 6 40 
 
All the patients had either T3 or T4 disease.  
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N Stage 
 
Table 20 N Stage Distribution Total Gastrectomy 
N Stage 
 
Number of patients Percentage 
N0 5 33.3 
N1 3 20 
N2 4 26.7 
N3 3 20 
 
5 patients had N0 disease, 3 patients had N1 disease, 4 patients had N2 disease and 3 
patients had N3 disease. 
 
 
M Stage 
 
Table 21 M Stage Distribution Total Gastrectomy 
 M Stage 
 
Number of patients Percentage 
M0 15 100 
M1 0 0 
 
None of the patients in this group had metastatic disease.   
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Exocrine pancreatic deficiency following total gastrectomy 
 
Number of patients who completed the stool elastase analysis = 10 
Using <200 μg elastase/g faeces as exocrine pancreatic deficiency cut-off: 
 
Number of patients who were included for analysis (had normal stool elastase 
preoperatively = 6  
 
Out of these 6 patients included, only one patient was newly found to have abnormally 
low stool elastase postoperatively. 
 
Incidence of exocrine pancreatic deficiency following total gastrectomy using <200 
μg elastase/g faeces = 16.7% 
 
 
Exocrine Pancreatic deficiency: Subtotal vs Total gastrectomy 
 
Table 22 Exocrine Pancreatic Deficiency: Subtotal vs total gastrectomy 
Surgery Normal 
Elastase 
Abnormal 
elastase 
Pearson chi-
square 
p value 
Subtotal 
gastrectomy 
12 
(60%) 
8 
(40%) 
1.110 0.380 
Total 
gastrectomy 
5 
(83.3%) 
1 
(16.7) 
 
 
There was no statistical difference between subtotal and total gastrectomy among 
patients who developed exocrine pancreatic deficiency following surgery. 
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Overall Exocrine pancreatic deficiency in any gastrectomy 
 
Number of patients who had normal pre-operative stool elastase using <200 μg 
elastase/g faeces cut-off = 26 
 
Number of patients who developed exocrine pancreatic deficiency following 
gastrectomy using <200 μg elastase/g faeces = 9 
 
Incidence of exocrine pancreatic deficiency following gastrectomy using <200 μg 
elastase/g faeces = 34.6% 
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Timing of post-operative sampling 
 
 
 
 
 
 
 
Figure 10 Timing of post-operative sampling Subtotal gastrectomy on Left and Total gastrectomy on Right 
  
 
 
 
                               
                  Figure 11 Timing of post-operative sampling All gastrectomy patients 
 
 
Sub-total Gastrectomy Total Gastrectomy 
All Gastrectomy Patients in study 
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Table 23 Timing of post-operative stool elastase testing 
Time of stool elastase testing from surgery Number of patients 
<= 1 month 12 
>1 month to < =3 months 3 
>3 months to <=6 months 6 
>6months 5 
TOTAL 26 
 
 (This table includes only patients who completed the study and had a normal pre-
operative stool elastase value.) 
 
Independent sample T test was was used to assess if there was any statistical 
significance between the post-operative elastase result and the timing of post-operative 
sampling. There was no statistical significance between post-operative elastase results 
and timing of post-operative sampling. (p=0.737) 
 
 
Independent sample T test was was used to assess if there was any statistical 
significance between the type of surgery(subtotal and total gastrectomy) and the timing 
of post-operative sampling. There was no statistical significance between subtotal and 
total gastrectomy. (p=0.737)  
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Quality of life assessment following Gastrectomy 
 
Year-wise distribution 
 
Table 24 Year-wise distribution of gastrectomy surgeries 
 
 
79 patients underwent gastrectomy for adenocarcinoma stomach during the study 
period. (2017) Prior to 2017, 246 patients had undergone gastrectomy for 
adenocarcinoma stomach in the years 2013 to 2016. 77, 50, 55 and 64 patients 
underwent gastrectomy in 2013, 2014, 2015 and 2016 respectively. 
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Table 25 Distribution of patients who were alive, dead or not reachable at the time of 
interview 
Groups  Number of patients Percentage 
Alive and contactable 179 55.1 
Died 110 33.8 
Not reachable 36 11.1 
 
Only 179 patients (55.1%) were confirmed to be alive at the time of interview and 
participated in the quality of life survey. 110 patients were reported to be died at the 
time of interview.  36 patients were lost to follow up.  
Gender distribution 
Table 26 Gender Distribution of Gastrectomy patients  
 
 
There were 221 male patients which constituted 68 % of the patients and 104 female 
patients which constituted 32 % of the study population. 
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Gastrectomy type 
Table 27 Gastrectomy Type Distribution 
 
81 patients underwent total gastrectomy and the rest 244 patients underwent subtotal 
gastrectomy.  
Method of surgery 
  
Table 28 Method of Surgery Distribution 
 
315 patients underwent open gastrectomy. 4 patients underwent laparoscopy assisted 
gastrectomy and 6 patients underwent totally laparoscopic gastrectomy.  
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Upfront surgery 
Table 29 Upfront Surgery vs Surgery after neoadjuvant therapy 
 
Majority of the patients 82% underwent upfront surgery and remaining 18% underwent 
neoadjuvant therapy followed by adjuvant therapy.  
 
Anastomotic leak 
Table 30 Anastomotic Leak Distribution among gastrectomy patients 
 
 
Anastomotic leak rate was 13 % among the gastrectomy patients.  
Upfront 
surgery, 
267, 
82%
Neoajuvant 
therapy followed 
by surgery , 58, 
18%
UPFRONT SURGERY VS NEOADJUVANT   N=325
Upfront surgery Neoajuvant therapy followed by surgery
41, 13%
284, 87%
ANASTOMOTIC LEAK   N-325
Yes No
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Reoperation rate 
Table 31 Re-operation distribution among gastrectomy patients 
 
 
The re-operation rate was 13 % among the gastrectomy patients. 
 
Comorbidities 
Table 32 Distribution of comorbidities among gastrectomy patients 
 
Hypertension was the most common comorbidity followed by diabetes and coronary 
artery disease.  
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Proximal resection margin 
Table 33 Positive Proximal Resection Margin Distribution 
 
 
Distal resection margin 
 
Table 34 Positive Distal Resection Margin Distribution 
 
 
The proximal resection was positive   in 7 % of the surgeries and the distal resection 
margin was positive in 11% of the surgeries.  
Yes, 22, 7%
No, 303, 93%
POSITIVE PROXIMAL RESECTION MARGIN,  N=325
Yes No
Yes, 37, 11%
No, 288, 89%
POSITIVE DISTAL RESECTION MARGIN,   N=325
Yes No
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Resection intent 
 
Table 35 Resection Intent Distribution 
 
 
81 % of the patients underwent gastrectomy with curative intent. 19 % of the patients 
underwent palliative gastrectomy. 
  
Palliative, 61, 
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Curative, 264, 
81%
N=325
Palliative Curative
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TNM Staging 
T Stage 
Table 36 T Stage Distribution among Gastrectomy patients 
 
 
N Stage 
 
Table 37 N Stage Distribution among Gastrectomy patients 
N stage No. of patients Percentage 
0 61 18.8 
1 75 23.1 
2 73 22.5 
3 116 35.7 
 
 
M Stage 
 
Table 38 M Stage Distribution among Gastrectomy patients 
M stage No. of patients Percentage 
0 317 97.5 
1 8 2.5 
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Symptom scales 
 
Symptom scale assessed include dysphagia, pain, reflux symptoms and eating 
restrictions. Symptom score of more than or equal to 50 were considered as severe and 
symptom scores from 1 to 49 were classified as mild symptoms and symptom score of 
0 was considered as no symptoms.  
 
Dysphagia Symptom scale 
 
 
Figure 12 Dysphagia Symptom Score Distribution 
 
Dysphagia was assessed using questions Q1 to Q3 on the Quality of life questionnaire. 
One patient in the 2017 group had severe symptoms of dysphagia. One patient had mild 
symptoms of dysphagia in 2014 and 2017. Two patients had mild symptoms of 
dysphagia in 2015. No patient had severe symptoms of dysphagia in the years 2013, 
2014, 2015 and 2016.  
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Pain Symptom scale 
 
 
Figure 13 Pain Symptom Score Distribution 
 
Pain symptom was assessed using questions Q4 to Q7 in the quality of life 
questionnaire. 4 patients (6.7%) operated in the year 2017 had severe symptoms, 38 
patients (63.3%) had mild symptoms. 18 patients (30%) had no symptoms of pain. Only 
one patient operated in the year 2016 had severe symptoms and 17 patients (54.8%) had 
mild symptoms, 13 patients (41.9%) had no symptoms. No patients operated in the years 
2013, 2014 and 2015 had severe pain symptoms. 9 patients (39.1%) operated in the year 
2015 had mild symptoms and 14 patients (60.9%) had no symptoms of pain. 14 patients 
(43.7%) of the patients operated in the year 2014 had mild pain and 18 patients (56.3%) 
had no symptoms. 17 patients (51.5 %) of the patients operated in the year 2013 had 
mild symptoms of pain and 16 patients (48.5%) had no symptoms of pain. 
  
48.5 56.3
60.9
41.9
30
51.5 43.7
39.1
54.8
63.3
0 0 0 3.2 6.7
0
20
40
60
80
100
120
2013 2014 2015 2016 2017
P
er
ce
n
ta
ge
 o
f 
p
at
ie
n
ts
Year
PAIN
No symptoms Mild Severe
90 
 
Reflux symptoms 
 
 
Figure 14 Reflux Symptom Score Distribution 
 
Reflux symptoms were assessed from questions Q8 to Q10 on the quality of life 
questionnaire. Only one patient operated in the year 2016 had severe symptoms of 
reflux. No patients operated in the years 2013, 2014, 2015 and 2017 had severe reflux 
symptoms. The number of patients who had mild reflux symptoms were 17(51.5%), 
17(53.1%), 12(52.2%), 14(43.8%) and 21(35%) in the years 2013, 2014, 2015, 2016 
and 2017 respectively. The number of patients who had no reflux symptoms were 
16(48.5%), 15(46.9%), 11(47.8%), 17(53.1%) and 39(65%) in the years 2013, 2014, 
2015, 2016 and 2017 respectively. 
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Eating restriction symptom scale 
 
 
Figure 15 Eating Restriction Symptom Score Distribution
 
Eating restriction were assessed using question numbers Q11 to Q14 on the quality of life 
questionnaire.  2 patients operated in the year 2016 and 2017 had severe eating restriction. The 
number of patients operated in the years 2013, 2014, 2015, 2016 and 2017 who had mild eating 
restrictions were 32(97%), 26(81.2%), 16(69.6%), 18(58.1%) and 38(63.3%) respectively. 
1(3%), 6(18.8%), 7(30.4%), 11(35.5%) and 20(33.3%) patients operated in the years 2013, 
2014, 2015, 2016 and 2017 had no symptoms of eating restriction. 
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Overall quality of life 
 
 
Figure 16 Quality of Life Distribution 
 
Overall quality of life was assessed using question numbers Q18 and Q19 of the quality of life 
questionnaire. Median score was 66.67 and was taken as average quality of life. Patients with 
scores higher than 66.67 were considered as good quality of life and patients with scores less 
than 66.67 were considered as below average quality of life. 46.7% of patients operated in 2017 
had good quality of life. Only 3% of patients operated in the year 2013 had good quality of life. 
3.1% patients operated in 2014, 22.6% patients in 2016 and 8.3 5 patients in 2017 had below 
average quality of life. 97%, 81.3%, 78.3%, 61.3% and 45% of patients operated in the years 
2013, 2014, 2015, 2016 and 2017 respectively had average quality of life. 
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Total Vs Subtotal gastrectomy 
 
Table 39 Total vs Subtotal Gastrectomy QOL and Symptom Score analysis 
VARIABLE GASTRECTOMY N MEAN(S.D) MEAN 
DIFFERENCE(95%CI) 
P VALUE 
DYSPHAGIA Total 37 0 -1.33 
(-2.56--.098) 
0.035 
Subtotal 142 1.3(7.4) 
PAIN Total 37 10.4(13.1) -1.61 
(-7.31-4.09) 
0.577 
Subtotal 142 12.0(16.2) 
REFLUX 
SYMPTOMS 
Total 37 10.8(13.0) -.38 
(-5.38-4.62) 
0.881 
Subtotal 142 11.2(13.9) 
EATING 
RESTRICTIONS 
Total 37 19.1(15.6) -1.16 
(-6.57-4.25) 
0.673 
Subtotal 142 20.3(14.7) 
QOL Total 37 60.9(10.4) -.40 
(-4.58-3.79) 
0.851 
Subtotal 142 70.3(11.6) 
 
Independent sample T test was used to assess the difference between the type of 
gastrectomy and symptom scales and quality of life. There was no statistical difference 
between the two groups in symptoms such as pain, reflux, eating symptoms and overall 
quality of life. There was statistical difference between the two types of surgery in 
dysphagia symptom scale. (p=0.035) 
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Method of surgery (Laparoscopy vs Laparoscopy assisted vs Open 
surgery) 
Table 40 Method of surgery QOL and Symptom Score analysis 
VARIABLE SURGERY 
METHOD  
N MEAN(S.D) P VALUE 
DYSPHAGIA Totally 
Laparoscopy 
5 0 0.888 
Laparoscopy 
assisted 
4 0 
Open 170 1.11(6.8) 
PAIN Totally 
Laparoscopy 
5 10(10.87) 0.886 
Laparoscopy 
assisted 
4 8.3(6.8) 
Open 170 11.76(15.6) 
REFLUX 
SYMPTOMS 
Totally 
Laparoscopy 
5 4.44(6.09) 0.546 
Laparoscopy 
assisted 
4 11.11(15.7) 
Open 170 11.31(13.7) 
EATING 
RESTRICTIONS 
Totally 
Laparoscopy 
5 10(9.1) 0.251 
Laparoscopy 
assisted 
4 25(6.8) 
Open 170 20.25(15) 
QOL Totally 
Laparoscopy 
5 73.3(9.1) 0.683 
Laparoscopy 
assisted 
4 66.67(0) 
Open 170 70.22(11.5) 
 
ANOVA (Analysis of variance) was used to assess the statistical difference between the 
method of surgery and symptom scores and quality of life. This showed no statistical 
significance.  
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Anastomotic leak 
 
Table 41 Anastomotic Leak QOL and Symptom Score analysis 
VARIABLE ANASTOMOTIC 
LEAK 
 
N MEAN(S.D) MEAN 
DIFFERENCE(95%CI) 
P VALUE 
DYSPHAGIA YES 24 1.39(6.8) .385 
(-2.49-3.26) 
0.79 
NO 155 1.00(6.6) 
PAIN YES 24 11.11(14.5) -.61 
(-7.39-6.17) 
0.86 
NO 155 11.72(15.8) 
REFLUX 
SYMPTOMS 
YES 24 11.11(14.3) .00 
(-5.94- 5.94) 
1.0 
NO 155 11.11(13.6) 
EATING 
RESTRICTIONS 
YES 24 16.32(15.2) -4.33 
(-11.12-2.47) 
0.18 
NO 155 20.65(14.7) 
QOL YES 24 70.83(12.3) .70 
(-4.75-6.15) 
0.78 
NO 155 70.13(11.2) 
 
 
Independent sample T test was used to assess the difference between the patients who 
had anastomotic leak in postoperative period and symptom scales and quality of life. 
There was no statistical difference between the two groups in symptoms such as 
dysphagia, pain, reflux, eating symptoms and overall quality of life.  
 
  
96 
 
Reoperation 
 
Table 42 Re-operation QOL and Symptom Score analysis 
VARIABLE REOPERATION N MEAN(S.D) MEAN 
DIFFERENCE(95%CI) 
P VALUE 
DYSPHAGIA Yes 27 1.23(6.42) 1.39(-2.53 -2.95) 0.88 
No 152 1.02(6.69) 
PAIN Yes 27 10.80(14.21) 3.27(-7.44-5.47) 0.76 
No 152 11.79(15.89) 
REFLUX 
SYMPTOMS 
Yes 27 10.29(13.76) 2.87(-6.62-4.68) 0.74 
No 152 11.26(13.71) 
EATING 
RESTRICTIONS 
Yes 27 17.90(15.10) 3.10(-8.66-3.57) 0.41 
No 152 20.45(14.79) 
QOL Yes 27 68.59(9.81) 2.41(-6.67-2.84) 0.43 
No 152 70.50(11.58) 
 
 
Independent sample T test was used to assess the difference between the patients who 
had re-operation and symptom scales and quality of life. There was no statistical 
difference between the two groups in symptoms such as dysphagia, pain, reflux, eating 
symptoms and overall quality of life.  
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Upfront surgery 
 
Table 43 Upfront Surgery QOL and Symptom Score analysis 
VARIABLE UPFRONT 
SURGERY 
N MEAN(S.D) MEAN 
DIFFERENCE(95%CI) 
P VALUE 
DYSPHAGIA Yes 147 1.29(7.30) 1.28 
(0.09-2.48) 
0.04 
No 32 0 
PAIN Yes 147 11.28(15.75) -2.0 
(-8.02-4.02) 
0.51 
No 32 13.28(15.10) 
REFLUX 
SYMPTOMS 
Yes 147 12.32(14.07) 6.76 
(2.48-11.05) 
0.002 
No 32 5.56(10.18) 
EATING 
RESTRICTIONS 
Yes 147 20.86(14.84) 4.46 
(-1.23-10.14) 
0.12 
No 32 16.41(14.43) 
QOL Yes 147 69.06(10.90) -6.46 
(-11.09 - (-1.82 )) 
0.007 
No 32 75.52(11.96) 
 
 
Independent sample T test was used to assess the difference between the patients who 
underwent upfront surgery against those who had neoadjuvant therapy followed by 
surgery and symptom scales and quality of life. There was no statistical difference 
between the two groups in symptoms such as pain and eating symptoms. However, there 
was statistical difference between the two groups in dysphagia symptom scale (p=0.04), 
reflux symptom scale (p=0.002) and overall quality of life. (p=0.007) 
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Proximal margin 
 
Table 44 Positive Proximal Resection Margin QOL and Symptom Score analysis 
VARIABLE PROXIMAL 
MARGIN 
N MEAN(S.D) MEAN 
DIFFERENCE(95%CI) 
P VALUE 
DYSPHAGIA Positive 4 0 -1.07 
(-7.71-5.55) 
0.75 
Negative 175 1.08(6.70) 
PAIN Positive 4 22.91(25.80) 11.54 
(-4.0-27.07) 
0.14 
Negative 175 11.38(15.33) 
REFLUX 
SYMPTOMS 
Positive 4 16.67(14.34) 5.68 
(-7.99- 19.35) 
0.41 
Negative 175 10.98(13.69) 
EATING 
RESTRICTIONS 
Positive 4 25.0(18.00) 5.05 
(-9.77 -19.86) 
0.50 
Negative 175 19.95(14.79) 
QOL Positive 4 66.67(0.0) -3.64 
(-5.35 – (-1.93)) 
0.00 
Negative 175 70.30(11.45) 
 
 
Independent sample T test was used to assess the difference between the presence of 
positive proximal margin on the resection specimen and symptom scales and quality of 
life. There was no statistical difference between the two groups in symptoms such as 
dysphagia, pain, reflux and eating symptoms. However, there was statistical difference 
between the presence of positive margin on the resection specimen and overall quality 
of life (p=0.00) 
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Distal margin 
 
Table 45 Positive Distal Resection Margin QOL and Symptom Score analysis 
VARIABLE DISTAL 
MARGIN 
N MEAN(S.D) MEAN 
DIFFERENCE(95%CI) 
P VALUE 
DYSPHAGIA Positive 17 0 -1.17(-4.51 – 2.17) 0.49 
Negative 162 1.17(6.96) 
PAIN Positive 17 7.84(11.96) -4.19(-12.05 – 3.66) 0.29 
Negative 162 12.04(15.93) 
REFLUX 
SYMPTOMS 
Positive 17 13.07(15.33) 2.17(-4.73 – 9.06) 0.54 
Negative 162 10.91(13.54) 
EATING 
RESTRICTIONS 
Positive 17 24.02(11.74) 4.37(-2.03 – 10.77) 0.17 
Negative 162 19.65(15.08) 
QOL Positive 17 69.79(9.07) -0.48(-6.36 – 5.40) 0.87 
Negative 162 70.27(11.56) 
 
 
Independent sample T test was used to assess the difference between the presence of 
positive distal margin on the resection specimen and symptom scales and quality of life. 
There was no statistical difference between the two groups in symptoms such as 
dysphagia, pain, reflux, eating symptoms and overall quality of life.  
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Resection intent 
 
Table 46 Resection intent QOL and Symptom Score analysis 
VARIABLE RESECTION 
INTENT 
N MEAN(S.D) MEAN 
DIFFERENCE(95%CI) 
P VALUE 
DYSPHAGIA Palliative 23 0 -1.21 
(-4.14 – 1.71) 
0.415 
Curative 156 1.21(7.09) 
PAIN Palliative 23 6.88(9.28) -5.46 
(-10.15 – (-0.76)) 
0.024 
Curative 156 12.34(16.24) 
REFLUX 
SYMPTOMS 
Palliative 23 12.56(15.46) 1.66 
(-4.38 – 7.71) 
0.588 
Curative 156 10.90(13.44) 
EATING 
RESTRICTIONS 
Palliative 23 19.93(13.93) -0.16 
(-6.58 – 6.26) 
0.962 
Curative 156 20.09(14.99) 
QOL Palliative 23 68.84(11.57) -1.59 
(-6.60  - 3.42) 
0.532 
Curative 156 70.43(11.32) 
 
Independent sample T test was used to assess the difference between the resection intent 
such as palliative or curative and symptom scales and quality of life. There was no 
statistical difference between the two groups in symptoms such as dysphagia, reflux, 
eating symptoms and overall quality of life. There was statistical difference between 
the two resection intent in pain symptom scale. (p=0.024) 
 
T Stage 
ANOVA (Analysis of variance) was used to assess the statistical difference between the 
method of surgery and symptom scores and quality of life. This showed no statistical 
significance. 
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N Stage 
ANOVA (Analysis of variance) was used to assess the statistical difference between the 
method of surgery and symptom scores and quality of life. This showed no statistical 
significance. 
M Stage 
 
Table 47 M Stage QOL and Symptom Score analysis 
VARIABLE M stage N MEAN(S.D) MEAN 
DIFFERENCE(95%CI) 
P VALUE 
DYSPHAGIA 0 176 1.07(6.69) 1.07(-6.57 – 8.71) 0.78 
1 3 0 
PAIN 0 176 11.41(15.57) -13.59(-31.47 – 
4.29) 
0.135 
1 3 25(14.43) 
REFLUX 
SYMPTOMS 
0 176 10.86(13.64) -15.06(-29.60 – (-
0.53)) 
0.046 
1 3 25.93(6.42) 
EATING 
RESTRICTIONS 
0 176 20.22(14.76) 9.11(-7.92 – 26.13) 0.29 
1 3 11.11(19.25) 
QOL 0 176 70.29(11.42) 3.62(-9.43 – 16.67) 0.59 
1 3 66.67(0) 
 
 
Independent sample T test was used to assess the difference between the patients who 
had metastatic disease and symptom scales and quality of life. There was no statistical 
difference between the two groups in symptoms such as dysphagia, pain, reflux, eating 
symptoms and overall quality of life. 
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Quality of life in relation to time 
 
In bivariate analysis, as the follow up time period increases by a month, the quality of 
life score reduces by 2. And this observation was statistically significant. (p value 0.045) 
Variables T Lower Bound Upper bound P value 
Follow up period -2.019 -0.177 -0.002 0.045 
 
In multivariate analysis, after adjusting for the factors such as age, gender, 
comorbidities, anastomotic leak, re-operation, Metastatic disease (M stage) and 
resection intent (Palliative or curative), as the follow up time period increases by a 
month, the quality of life score decreases by 2 points. 
 
Variables T Lower Bound Upper bound P value 
Follow up period -2.182 -.198 -.010 .031 
Gender .510 -2.881 4.885 .611 
Age -.026 -.155 .151 .979 
Diabetes .000 -5.252 5.253 1.000 
Hypertension -.523 -7.115 4.135 .602 
Asthma -.645 -13.791 7.003 .520 
CAD -.841 -10.491 4.225 .402 
COPD .185 -12.764 15.400 .854 
Thyroid -.537 -10.928 6.256 .592 
Reoperation 1.662 -1.256 14.610 .098 
Anastomotic leak -1.645 -15.206 1.384 .102 
M stage -.865 -19.903 7.780 .389 
Resection type -.146 -5.827 5.025 .884 
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Average survival period 
 
Figure 17 Average post-operative survival period 
Minimum = 1, Maximum = 65 
 
110 patients who underwent gastrectomy for adenocarcinoma stomach were reported to be 
dead at the time of interview. The mean survival of the patients was 19.65 months.  
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DISCUSSION 
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The incidence of exocrine pancreatic function following subtotal gastrectomy using 
stool elastase was found to be 40% in this study. In comparison with literature, with 
reference to Langenbecks Arch Chir. 1985;367(21):41-50 , exocrine pancreatic 
deficiency found among post subtotal gastrectomy patients with billroth II 
reconstruction was found to be 69.7%  
 
The incidence of exocrine pancreatic function following total gastrectomy using stool 
elastase was found to be 16.7% in this study. In comparison with literature, with 
reference to AmJ Gastroenterol. 1996 Feb;91(20):341-7., exocrine pancreatic 
insufficiency was found among post total gastrectomy patient to be 100%. 
 
In this study, the overall incidence of exocrine pancreatic insufficiency following 
gastrectomy (including both total and subtotal gastrectomy using <200 μg elastase/g 
faeces cut off) was 34.6%. Therefore, compared to the available western literature, the 
incidence was significantly lower in our population. This may be because of the dietary 
habits and fat content in Indian diet. All the patients were assessed for clinical symptoms 
of steatorrhoea or lipid malabsorption in the post-operative period at the time of testing 
stool elastase. All the patients diagnosed to have decreased stool elastase levels, had 
sub-clinical exocrine pancreatic insufficiency in the post-operative period following 
gastrectomy.  That is, none of our patients had clinically significant steatorrhoea or fat 
malabsorption   
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We have used <200 μg elastase/g faeces as cut off for diagnosing exocrine pancreatic 
insufficiency(35). Patients who had a normal pre-operative stool elastase and developed 
an abnormally low value of stool elastase following gastrectomy were considered to 
have developed exocrine pancreatic insufficiency following surgery. The average 
timing of the stool elastase testing was 90 days, from the time of surgery.  However, the 
time of testing postoperative testing ranged from 14 days to 351 days. This wide 
difference in the post-operative follow up visit was due to the varied geographic location 
of the patients and the patient logistics in relation to the centre where they prefer to take 
adjuvant therapy. Some patients preferred to continue further adjuvant therapy at 
hometown and had come for the final post-operative review in General surgery OPD 
within 1 month. Some patients had immediately left to hometown following discharge 
from hospital and had returned after 6-8 months back to our institute for follow-up when 
the post-operative stool elastase testing was done. However, statistically, there was no 
significant difference between the time of post-operative testing and the incidence of 
exocrine pancreatic insufficiency. 
 
Our patients do not receive pancreatic enzyme supplementation on a routine basis post-
operatively. Also exocrine pancreatic function testing is not done routinely in our 
patients post-operatively. From this study, we can infer that that incidence of exocrine 
pancreatic insufficiency is low compared to the western data. Hence our patients do not 
require routine post-operative supplementation of pancreatic enzymes.  However, 
selective administration of pancreatic supplement therapy might benefit the sub-group 
of patients who develop abnormally low stool elastase in the postoperative period which 
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in turn refers to exocrine pancreatic insufficiency. In India, direct testing methods for 
exocrine pancreatic function are not available. The only available method of testing 
exocrine pancreatic function is through indirect testing methods such as stool elastase. 
 
Stool elastase testing can be done in patients postoperatively in all gastrectomy patients 
and selective administration of pancreatic enzyme supplementation can be done in those 
patients who have developed exocrine pancreatic insufficiency. This forms a cost-
effective treatment strategy in handling post-gastrectomy exocrine pancreatic 
insufficiency.   
 
18 patients included in the study had abnormally low stool elastase pre-operatively. 
However, stool elastase is unaffected/ minimally affected by symptoms such as gastric 
outlet obstruction or bleeding seen in gastric carcinoma. Hence, further analysis may be 
needed substantiate the prevalence of subclinical pancreatic insufficiency in our normal 
population. 
 
The long-term impact of gastrectomy on exocrine pancreatic function is unclear. This 
warrants further studies with longer post-operative follow-up periods to see the trend of 
exocrine pancreatic function in these patients. If a patient was diagnosed to have 
exocrine pancreatic insufficiency in the postoperative period and was started on 
pancreatic enzyme replacement therapy, then stool elastase testing could be done after 
6 months to 1 year and the need for continuation of pancreatic enzyme replacement 
therapy can be decided based on it.  
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Majority of our stomach cancer patients who underwent gastrectomy had average 
quality of life with mean score of 66.67. It is seen from the study that the number of 
patients who had a good quality of life were more in the 1 year follow up period than 5 
year follow up patients. This can be attributed for the fact that these patients would have 
suffered from the disease and had symptoms of obstruction and bleeding. Immediately 
following surgery, patients tend to feel better since they have been relieved of their 
acute symptoms and is able to tolerate a normal diet. Patients who are at longer post-
operative period such as 3,4 and 5 years have been used to the postoperative anatomy 
for some time and have higher expectations regarding the quality of life.  Multivariate 
analysis, after adjusting for the factors such as age, gender, comorbidities, anastomotic 
leak, re-operation, Metastatic disease (M stage) and resection intent (Palliative or 
curative) showed that as the follow up time period from the time of surgery increases 
by a month, the quality of life score decreases by 2 points.  
Symptoms of dysphagia were very low in our post-operative patients although one 
patient complained of severe symptoms of dysphagia in the 1 year follow up period. 
6.7% of patients in the 1 year follow up period complained of severe pain and 3.2% 
patients in the 2 year follow up period complained of pain. No patient complained of 
severe pain symptoms among the patients operated in 2013, 2014 and 2015.  
 
Mild reflux symptoms were seen more among patients operated in 2013(51.5%), 
2014(53.1%) and 2015(52.2%) compared to 2016(43.8%) and 2017(35%). Most 
patients (65%) in the 1 year follow up group 2017 had no symptoms of reflux.  Severe 
109 
 
eating restrictions were seen in 6.4% of patients operated in 2016 and 3.34% of patients 
operated in 2017. No patient operated in 2013, 2014 and 2015 had severe eating 
restrictions.  
 
Only dysphagia symptoms had statistically significance (p=0.035) on comparing the 
groups of patients who underwent total and subtotal gastrectomy. There was no 
statistical significance as far as the other symptoms such as pain, reflux and eating 
restriction. Also there was no change in the overall quality of life.  
 
There was no change in the symptom score and overall quality of life among patients 
who had an anastomotic leak in the post-operative period. Also there was no change in 
the symptom score and overall quality of life among patients who had a re-operation in 
the post-operative period. Although the overall cancer related survival may be 
influenced by the occurrence of anastomotic leak, in this study there was no statistical 
difference in their quality of life.  
 
Patients who had an upfront surgery had statistically significant higher dysphagia 
symptom score and reflux symptom score compared to the patients who had surgery 
after neoadjuvant therapy. Also the overall quality of life had slightly better score 
among patients who had surgery after neoadjuvant therapy. This can be attributed to the 
fact that the patients who had upfront surgery had advanced disease and had come with 
obstruction symptoms or bleeding symptoms which usually warrant an upfront surgery. 
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Presence of a positive proximal or distal margin on the resection specimen did not have 
a significant influence of the symptom score of the patients who were alive at the time 
of interview. However, patients with positive proximal margin had slightly lower 
quality of life score compared to those who had negative proximal margin which was 
found to be statistically significant. Positive distal resection margin did not have a 
significant influence on the quality of life of patients who survived so far.  
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LIMITATIONS 
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Since patients were from a wide geographical background, long-term follow up was 
low.  Post-operative stool sampling was done on various post-operative periods in 
different patients. This was because of logistic reasons in relation to patient continuing 
adjuvant therapy at our centre or at hometown. Patients who were completely obstructed 
were unable to give a stool sample for pre-operative stool elastase testing and could not 
be included in the study.   Some patients who underwent gastrectomy for gastric cancer 
were unable to be contacted for assessment of quality of life.  
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CONCLUSIONS 
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1. The incidence of exocrine pancreatic insufficiency was low in our population 
compared to the available Western data. Only 34.6% our patients developed sub-
clinical exocrine pancreatic insufficiency following gastrectomy for gastric 
cancer. 
2. Routine supplementation of pancreatic enzyme to all patients undergoing 
gastrectomy may not be required.  
3. However, screening for pancreatic exocrine insufficiency by stool elastase 
testing, in the subgroup of patients who are malnourished or have symptoms of 
fat malabsorption may help detect this problem, which can be addressed 
effectively by exocrine pancreatic supplementation. Long-term follow up of 
these patients would help to assess the trend in exocrine pancreatic function 
following gastrectomy and would help in patient directed therapy.  
4. There was no statistical difference between total and subtotal gastrectomy with 
the incidence of exocrine pancreatic insufficiency.  
5. More number of patients at 1-year follow-up have higher pain and eating 
restriction score which decreases as the follow up time period increases. 
6. The mean overall quality of life score was 70.2 (Range 0 – 100). 
7. Quality of life score was not influenced by the type of gastrectomy, method of 
surgery, stage of disease at presentation or the resection intent. 
8. As the follow up time period from the time of surgery increases, the overall 
quality of life score decreases.   
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Appendix III – Information Sheet  
 
Exocrine pancreatic insufficiency in post gastrectomy patients and quality of life in 
patients following gastric resection for gastric malignancy 
Patient Information Sheet 
INVITATION: 
You are invited to participate in the study, because you are having a surgical procedure in 
General Surgery Department at CMC Hospital, Vellore, and your doctor has determined that 
you may be eligible for stool elastase testing for the study and assessment of quality of life 
following surgery. 
PURPOSE OF RESEARCH: 
Gastrectomy for gastric cancer is a major procedure causing significant morbidity to the patient and 
affects quality of life. One of the major problems following gastrectomy surgery is the malabsorption 
and weight loss caused by lipid malabsorption which in turn causes malabsorption of essential 
nutrients from the diet. One of the reasons for lipid malabsorption is pancreatic enzyme deficiency 
caused by the surgical procedure and the bypass reconstruction. This study aims to establish exocrine 
pancreatic deficiency following gastrectomy and assess the quality of life following gastric resection. 
For research purposes, we would like you to give a stool sample for testing (if needed) and fill up a 
questionnaire. In addition, we will collect information about your diagnosis and treatment from your 
medical records.  
Your decision whether or not to participate is entirely voluntary will not prejudice you or your 
medical care and your surgical procedure. Please ask any questions about anything you do not 
understand, before you decide to or not to participate in this study.  If you decide not to participate, 
the health care provided to you by the Surgery III unit or any other department at the Christian 
Medical College, will not be affected in any way.   
Are there any benefits to the study participants? 
Although you are not expected to benefit directly from participating in this study, you may make a 
significant contribution to the understanding of exocrine pancreatic deficiency following gastrectomy 
and quality of life following gastric resection. This information might help to alter or supplement 
medications and enzymes to patients following such procedures which can significantly decrease 
morbidity and help in improving the quality of life of gastrectomy patients. 
Will the participant be paid for the participation? 
You will not be paid for your participation in this study. 
Are there any side effects or risks to the participant? 
There are no physical risks to you from your participation in this study. Every effort will be made to 
keep your identity and information confidential. Your treatment would be the same irrespective of 
whether you are part of the study or not. 
How will the participants privacy be protected and who will use the health information of the 
participants? 
By agreeing to participate in this study, you provide authorisation for the researchers to your health 
information for research. Your treating doctor and the researchers will do everything possible to keep 
your medical information confidential.  The information will be stored in a password protected 
computer at the Surgery III-unit office in Paul Brand Building at CMC hospital, Vellore. 
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Is my permission voluntary and may I change my mind? 
Your permission is voluntary. In case you decide not to participate now, or if you decide to withdraw 
your participation in any point in the future, this decision will not influence or affect the further 
treatment that you receive from any of the departments of the Christian Medical College, Vellore. 
If I have additional questions, whom should I contact? 
Please take as much time as you need to think over whether or not you wish to participate. If you have 
any questions about this study, please contact Dr. Rajeevan.P.S in the Department of Surgery, Paul 
Brand Building (2nd floor), or by phone 08870427408 / 04162282079 (8 am to 4.30 pm) 
Can I keep this information sheet for my reference? 
This information sheet is to be kept by you after you have consented to participate in this project by 
signing the attached informed consent form. 
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Appendix IV- Consent Sheet 
 
Study Title:    EXOCRINE PANCREAS INSUFFICIENCY IN GASTRECTOMY PATIENTS AND 
ASSESSMENT OF QUALITY OF LIFE FOLLOWING GASTRIC RESECTION FOR GASTRIC 
MALIGNANCY 
 
Informed Consent form to participate in a research study  
Study Number: ____________ 
 
Subject’s Initials: ________      Subject’s Name: _________________________________ 
Hospital Number: _________ 
Date of Birth / Age: ___________________________  
Address and Phone Number: _________________________________________ 
                                                    _________________________________________ 
                                                     Phone:_________________________________________ 
(i)  I confirm that I have read and understood the information sheet dated ____________ for the above study 
and have had the opportunity to ask questions. [  ] 
(ii)  I understand that my participation in the study is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. [  ] 
(iii)  I understand that the Ethics Committee and the regulatory authorities will not need my permission to 
look at my health records both in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the trial. I agree to this access. However, I understand 
that my identity will not be revealed in any information released to third parties or published. [  ] 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided such a use is only 
for scientific purpose(s). [  ] 
(v)  I agree to take part in the above study. [  ] 
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Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
 
 
 
Date: _____/_____/______ 
Signatory’s Name: _________________________________        :  
 
Signature of the Investigator: ________________________  
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
 
Signature or thumb impression of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name & Address of the Witness: ______________________________ 
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Appendix V – Data collection Proforma 
 
EXOCRINE PANCREATIC INSUFFICIENCY FOLLOWING GASTRECTOMY PATIENTS 
AND QUALITY OF LIFE IN PATIENTS UNDERGOING GASTRIC RESECTION FOR 
MALIGNANCY 
 
Data collection sheet 
 
1. Questionnaire No:                                                                                                     
2. Date: 
3. Name: 
4. Hospital No: 
5. Age: 
6. Phone Number: 
7. Address: 
8. Diagnosis:  
9. Date of surgery: 
10. Surgery:  Subtotal gastrectomy / Total gastrectomy 
11. Method of surgery: Laparoscopic /Laparoscopic assisted/ Open 
12. Palliative/Curative: Palliative/Curative 
13. Extent of lymphadenectomy: 
14. Postop period at interview: --------------- months  
15. Type of anastomosis: 
16. Type of resection: No micro or macro metastasis/No macro metastasis/Macro metastasis 
17. Complications: 
a) Anastomotic leak:   Y/N 
b) Respiratory Failure:   Y/N 
c) Renal Failure:   Y/N 
d) Multiorgan failure:   Y/N 
e) Septic shock:   Y/N 
f) Chest infection:   Y/N 
g) Ileus:  Y/N 
h) Cardiac event:   Y/N 
i) Wound infection:    Y/N 
18. NeoAdjuvant therapy: Yes / No 
                        If yes,           i) Chemotherapy -  yes/no 
                                                                              ii)Radiotherapy  - yes/no 
19. Adjuvant therapy: Yes / No 
                        If yes,           i)Chemotherapy -  yes/no 
                                                                              ii)Radiotherapy  - yes/no 
 
 
             Histology: 
20. Tumor type: 
21. Tumor differentiation: 
22. Based on histology and surgical findings: 
                 Curative resection - No micro or macro metastasis 
                 Palliative resection - No macro metastasis / Macro metastasis  
23. Postoperative staging: T_N_M_                  
24. Eligible for Stool elastase testing   yes/ no 
                If yes,   
   a) Preoperative Stool elastase value ---------------  (  numerical value) 
                 Stool elastase     Normal /  Abnormal 
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                 If Abnormal,        Moderate / severe 
b) Preoperative Stool elastase value ---------------  (  numerical value) 
                 Stool elastase     Normal /  Abnormal 
                 If Abnormal,        Moderate / severe 
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Appendix VI – Quality of Life questionnaire  
 
QUALITY OF LIFE FOLLOWING GASTRECTOMY FOR CARCINOMA QUESTIONNAIRE 
Patients sometimes report that they have the following symptoms or problems. Please indicate the extent to 
which you have experienced these symptoms or problems during the past week. Please answer by circling the 
number that best applies to you. 
During the past week:                                                                               Not at           A        Quite        Very  
                                                                                                                                  All            Little         a Bit          
Much 
 
1. Have you had problems eating solid foods?                             1                 2                 3                        4    
 
2. Have you had problems eating liquidised or soft foods?          1                 2                   3                       4    
    
3. Have you had problems drinking liquids?                                1                2                    3                       4         
 
4. Have you had discomfort when eating?                                    1                 2                    3                      4    
 
5. Have you had pain in your stomach area?                                1                2                     3                      4 
 
6. Have you had discomfort in your stomach area?                      1                2                     3                     4 
 
7. Did you have a bloated feeling in your abdomen?                    1                 2                     3                     4    
   
8. Have you had trouble with acid or bile coming into your mouth? 1             2                  3                      4    
 
9. Have you had acid indigestion or heartburn?                             1                2                   3                       4    
 
10. Have you had trouble with belching?                                        1                 2                   3                      4    
 
11. Have you felt full up too quickly after beginning to eat?         1                 2                   3                       4    
 
12. Have you had trouble enjoying your meals?                               1             2                    3                       4    
 
13. Has it taken you a long time to complete your meals?             1               2                     3                       4   
 
14.  Have you had trouble with eating in front of other people?  1                2                     3                       4   
 
15. Do you have foul smelling stools?                                          1                 2                     3                       4    
 
16. How many times do you pass stools every day?      _____________________________ 
 
17. What is the consistency of stools?               Loose stools   /  Normal consistency  / Hard stools 
 
18. How would you rate your overall health during the past week? 
1             2           3            4           5            6          7  
               Very poor                                                              Excellent  
 
 
19. How would you rate your overall quality of life during the past week?  
                             1             2           3            4           5            6          7  
                       Very poor                                                              Excellent  
 
 
 
 
146 
 
 
147 
 
 
148 
 
 
149 
 
 
150 
 
 
  
151 
 
Appendix VII – Data Entry Sheet – Excel Spreadsheet 
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